Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The realization that alterations in inhibitor of apoptosis (IAP) proteins are found in many types of human cancer and are associated with chemoresistance, disease progression and poor prognosis, has sparked a worldwide frenzy in the development of small pharmacological inhibitors of IAPs. The development of such inhibitors has radically changed our knowledge of the signalling processes that are regulated by IAPs. Recent studies indicate that IAPs not only regulate caspases and apoptosis, but also modulate inflammatory signalling and immunity, mitogenic kinase signalling, proliferation and mitosis, as well as cell invasion and metastasis.

Original publication




Journal article


Nat Rev Cancer

Publication Date





561 - 574


Animals, Apoptosis, Caspase Inhibitors, Caspases, Humans, Inflammation, Inhibitor of Apoptosis Proteins, Lymphoma, B-Cell, Marginal Zone, NF-kappa B, Neoplasm Metastasis, Neoplasms, Signal Transduction, Toll-Like Receptors, Ubiquitin